Researchers sought to assess the risk of developing ALL in patients with multiple myeloma treated with lenalidomide.

Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA ...

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating ...

Sanofi SA (NASDAQ:SNY) released results from the IRAKLIA phase 3 study evaluating the non-inferiority of Sarclisa (isatuximab ...

Sanofi has reported results from its Phase III IRAKLIA trial of Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM).

Daratumumab therapy resulted in superior progression-free survival in frail patients with previously untreated multiple myeloma.

A phase 3 trial reveals that combining brentuximab vedotin with lenalidomide and rituximab improves survival in relapsed ...

Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies. Click here to find out why I ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myelomaSarclisa SC formulation added to ...